Patterns of liver injury in COVID-19 - a German case series.
Adult
Aged
Aged, 80 and over
Alanine Transaminase
/ blood
Antiviral Agents
/ adverse effects
Aspartate Aminotransferases
/ blood
Betacoronavirus
/ pathogenicity
Biomarkers
/ blood
COVID-19
COVID-19 Testing
Chemical and Drug Induced Liver Injury
/ blood
Clinical Laboratory Techniques
/ statistics & numerical data
Coronavirus Infections
/ complications
Electronic Health Records
/ statistics & numerical data
Female
Germany
/ epidemiology
Humans
Liver
/ drug effects
Liver Failure, Acute
/ blood
Liver Function Tests
/ statistics & numerical data
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ complications
Retrospective Studies
SARS-CoV-2
Young Adult
COVID-19 Drug Treatment
COVID-19
Liver
cohort study
hepatology
inflammation
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
27
6
2020
medline:
8
8
2020
entrez:
27
6
2020
Statut:
ppublish
Résumé
Reports of liver injury in patients with novel coronavirus disease 2019 (COVID-19) are emerging from China and the USA. A wide variety of liver function test abnormalities and few cases of severe liver failure have been reported. No data on the hepatic phenotype from Europe are available at current. We report a case series of 44 consecutive patients hospitalized for COVID-19 in Germany. At the time of admission, aspartate aminotransferase greater than the upper limit of normal was present in 70%, while alanine aminotransferase was elevated in 15.8%. Markers of cholestatic liver injury were altered only in a minority of patients. During hospitalization, 31% and 22% experienced increasing aspartate aminotransferase and alanine aminotransferase, respectively, when transaminases were normal at admission. Severe liver injury defined by 3×> upper limit of normal was observed in 9.1% over a mean time of 10.5 days. Importantly, patients exhibited cytotoxicity including lactate dehydrogenase and creatinine kinase elevations, but no signs of relevant liver function impairment. In summary, in a case series of hospitalized patients in Germany, cytotoxicity in the absence of severe liver dysfunction at admission and only few cases suggestive of severe liver injury during hospital were observed.
Sections du résumé
BACKGROUND
Reports of liver injury in patients with novel coronavirus disease 2019 (COVID-19) are emerging from China and the USA. A wide variety of liver function test abnormalities and few cases of severe liver failure have been reported. No data on the hepatic phenotype from Europe are available at current.
METHODS
We report a case series of 44 consecutive patients hospitalized for COVID-19 in Germany.
RESULTS
At the time of admission, aspartate aminotransferase greater than the upper limit of normal was present in 70%, while alanine aminotransferase was elevated in 15.8%. Markers of cholestatic liver injury were altered only in a minority of patients. During hospitalization, 31% and 22% experienced increasing aspartate aminotransferase and alanine aminotransferase, respectively, when transaminases were normal at admission. Severe liver injury defined by 3×> upper limit of normal was observed in 9.1% over a mean time of 10.5 days. Importantly, patients exhibited cytotoxicity including lactate dehydrogenase and creatinine kinase elevations, but no signs of relevant liver function impairment.
CONCLUSION
In summary, in a case series of hospitalized patients in Germany, cytotoxicity in the absence of severe liver dysfunction at admission and only few cases suggestive of severe liver injury during hospital were observed.
Identifiants
pubmed: 32588791
doi: 10.1177/2050640620931657
pmc: PMC7435007
doi:
Substances chimiques
Antiviral Agents
0
Biomarkers
0
Aspartate Aminotransferases
EC 2.6.1.1
Alanine Transaminase
EC 2.6.1.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
814-819Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
Dtsch Arztebl Int. 2020 Apr 17;117(16):271-278
pubmed: 32519944
Hepatology. 2020 Aug;72(2):389-398
pubmed: 32359177
J Hepatol. 2019 Apr;70(4):797-799
pubmed: 30635243
Nature. 2017 Jul 20;547(7663):350-354
pubmed: 28700576
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Gastroenterol Hepatol. 2017 Sep;14(9):503
pubmed: 28743983
Liver Int. 2009 Sep;29(8):1253-61
pubmed: 19040538
J Infect Dis. 2005 Jan 15;191(2):193-7
pubmed: 15609228
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Liver Int. 2019 May;39(5):812-814
pubmed: 31020772